{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-073747","form_type":"8-K","ticker":"IRWD","cik":"0001446847","company_name":"IRONWOOD PHARMACEUTICALS INC","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.903640+00:00","generated_at":"2026-06-13T18:55:42.880662+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Ironwood shareholders approve new equity plan and director slate at 2023 annual meeting","bullets":["All nine director nominees elected, including Mark Currie, Alexander Denner, Andrew Dreyfus, Jon Duane, Marla Kessler, Thomas McCourt, Julie McHugh, Catherine Moukheibir, Jay Shepard.","Non-binding advisory vote on executive compensation approved: 124,448,271 for, 2,240,534 against, 261,827 abstain.","Stockholders recommended future say-on-pay votes every year (121,938,287 for 1-year; broker non-votes 8,009,329).","Amended and Restated 2019 Equity Incentive Plan approved: 119,042,503 for, 7,783,479 against; adds up to 16,000,000 new shares plus prior plan forfeitures.","Ratification of Ernst & Young as auditor for 2023: 131,145,295 for, 3,631,560 against, 183,106 abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-073747","json":"https://secwatch.observer/filing/0001104659-23-073747.json","markdown":"https://secwatch.observer/filing/0001104659-23-073747.md","text":"https://secwatch.observer/filing/0001104659-23-073747.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/tm2319310d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T18:55:42.880662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21e2b85711671e3f37fc9274486bd74ffb271160","claim":"IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote on frequency of future say-on-pay votes (every year) at the 2023-06-20 meeting.","evidence_excerpt":"The stockholders recommended, on a non-binding advisory basis, that future non-binding advisory votes to approve the compensation of the Company’s named executive officers, be held once every year, based on the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay frequency"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-20"}],"fact_type":"shareholder_vote"},{"claim_id":"40784ceb37e035d6f1228b8497ee1656309ab819","claim":"IRONWOOD PHARMACEUTICALS INC shareholders approved Advisory vote to approve named executive officer compensation at the 2023-06-20 meeting.","evidence_excerpt":"The stockholders approved, on a non-binding advisory basis, the compensation paid to the Company’s named executive officers, as disclosed in the Company’s proxy statement for the Annual Meeting, based on the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-20"}],"fact_type":"shareholder_vote"},{"claim_id":"5126c66b779b7590eb5184e38e2213b6418883ab","claim":"IRONWOOD PHARMACEUTICALS INC shareholders approved Approval of Amended and Restated 2019 Equity Incentive Plan at the 2023-06-20 meeting.","evidence_excerpt":"The stockholders approved the Company’s Plan, based on the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-20"}],"fact_type":"shareholder_vote"},{"claim_id":"82ecd5829e1bf6e620c6503d447099b28e80a29b","claim":"IRONWOOD PHARMACEUTICALS INC shareholders approved Ratification of Ernst & Young LLP as independent auditor for 2023 at the 2023-06-20 meeting.","evidence_excerpt":"The stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2023, based on the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-20"}],"fact_type":"shareholder_vote"},{"claim_id":"a0ed674d85a67b3921ba03f6d40b843fc2e8139b","claim":"IRONWOOD PHARMACEUTICALS INC shareholders approved Election of nine directors at the 2023-06-20 meeting.","evidence_excerpt":"The stockholders elected nine director nominees, each to serve on the board of directors of the Company for a one-year term extending until the 2024 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified, or until his or her death, resignation or removal, based on the following votes:","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1446847/000110465923073747/0001104659-23-073747-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-20"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}